02196 Overview

Market Performance: The NASDAQ Golden Dragon China Index rose over 4%, with Alibaba ADR leading the charge by climbing 10%, contributing to a strong opening for the Hong Kong bourse, which saw the HSI open 350 points higher and close the morning session up 268 points.

Technology Sector Movements: In the technology sector, notable stocks like BABA-W and ALI HEALTH saw gains of 3.5% and 3.3% respectively, while other major players like TENCENT and JD-SW also experienced slight increases, despite some stocks like MEITUAN-W and BIDU-SW declining.

Pharmaceutical Sector Highlights: The 44th JPMorgan Healthcare Conference commenced in San Francisco, with several Chinese pharmaceutical companies participating, leading to significant gains for stocks such as REMEGEN, which surged 11.6%, and CSPC PHARMA, which jumped 5.7% after its innovative drug application was accepted.

AI Concept Stocks Decline: Several AI concept stocks, including SENSETIME-W and WEIMOB INC, experienced declines ranging from 3.3% to 4.2%, while other stocks like KNOWLEDGE ATLAS and MINIMAX-WP saw even steeper drops of 8.8% and 7.5% respectively.

Collaboration Agreement: FOSUN PHARMA signed a US$2.1 billion collaboration agreement with Pfizer for its preclinical small molecule GLP-1 drug, YP05002, positioning it favorably in the market.

Financial Impact: CLSA raised its earnings forecasts for FOSUN PHARMA, adjusting net profit predictions for 2025-2027 upwards by 1% to 2.4%, reflecting the positive financial implications of the collaboration.

Target Price Increase: Following the agreement, CLSA increased its target prices for FOSUN PHARMA's H-/A-shares from $29.6/RMB40.2 to $31.6/RMB42.4, maintaining an Outperform rating.

Market Activity: FOSUN PHARMA's stock saw a short selling of $10.30 million with a ratio of 12.189%, indicating notable market activity surrounding the company.

Fosun International Participation: Fosun International is participating in the China International Import Expo (CIIE) for the eighth consecutive year, showcasing innovative pharmaceuticals and high-end medical devices at their booth.

Focus on Healthcare Innovation: The company emphasizes its commitment to addressing unmet clinical needs in healthcare, leveraging global industrial advantages to promote cutting-edge technologies in China.

Chairman's Statement: Chairman Guo Guangchang highlighted the CIIE as a platform for China's development and international collaboration, aiming for high-level opening-up and global sharing of public products.

Short Selling Data: Fosun International has reported short selling of $5.45 million with a ratio of 28.397%, while Fosun Pharma has $16.21 million in short selling with a ratio of 16.975%.

Operating Revenue: FOSUN PHARMA reported a third-quarter operating revenue of RMB9.879 billion, reflecting a 5.46% decrease year-over-year.

Net Profit: The net profit attributable to shareholders increased by 4.52% year-over-year, amounting to RMB821 million, with an earnings per share (EPS) of RMB0.31.

Short Selling Activity: The company experienced short selling of $9.11 million, with a short selling ratio of 7.385%.

Stock Performance: FOSUN PHARMA's stock price decreased by 0.660, or 2.790%, with quotes delayed for at least 15 minutes.

Stock Ratings and Target Prices: BeOne Medicines Ltd. has a buy rating with a target price increase from US$323 to US$375, while several other companies like INNOVENT BIO and SKB BIO-B also received buy ratings with notable price increases.

Short Selling and Market Activity: Various stocks, including CSPC PHARMA and HENGRUI PHARMA, are experiencing significant short selling activity, with CSPC PHARMA being downgraded to neutral by UBS, indicating a shift in market sentiment.